จำหน่ายเกจวัดแรงดัน Pressure Gauge ทุกยี่ห้อ

ศูนย์รวมเครื่องมือวัดความดัน

Acquisition will add to Dover’s single-use element offering

Dover has entered right into a definitive settlement to amass Malema Engineering Corp, a US designer and manufacturer of high-precision, mission-critical flow-measurement and management devices for the biopharmaceutical, semiconductor and industrial sectors.
Image: dizain/Adobe Stock.
Malema’s products will expand Dover’s biopharma single-use manufacturing providing, which already contains Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with facilities in San Jose, California, Singapore, South Korea and India, Malema expects to generate roughly US$40 million–45 million in income through the full 12 months 2022.
When the deal closes, Malema will turn out to be a half of the PSG enterprise unit within Dover’s Pumps & Process Solutions phase.
digital pressure gauge see an amazing long-term progress alternative in the bioprocessing business driven by a robust and growing pipeline of effective novel biologic drugs, biosimilars, protein therapies, non-COVID mRNA vaccines, as well as budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, the rising adoption of more efficient single-use production processes supports a sturdy outlook for our choices of single-use elements to end-customers. We believe that pairing Malema’s know-how with our current portfolio of single-use pumps for biopharma processing will tremendously enhance the accuracy and worth proposition of our solutions to our customers.”

“We are methodically building out our biopharma platform by way of proactive capability additions, new product growth, and opportunistic acquisitions of highly-attractive area of interest part applied sciences,” said Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing expertise and further strengthens our sensor portfolio with new proprietary technology. In addition to enticing biopharma purposes, we count on sturdy development in the semiconductor area on the capacity enlargement and re-shoring tailwinds.”

Share